(Q35029566)

5 August 2017

1 reference

title

Molecular targets in acute myelogenous leukemia (English)

1 reference

5 August 2017

Derek L Stirewalt

1

1 reference

PubMed ID

12490207

5 August 2017

Soheil Meshinchi

series ordinal

2

1 reference

PubMed ID

12490207

5 August 2017

Jerald P Radich

series ordinal

3

1 reference

5 August 2017

1 March 2003

1 reference

5 August 2017

1 reference

5 August 2017

17

1 reference

5 August 2017

15-23

1 reference

5 August 2017

1

1 reference

p19ARF links the tumour suppressor p53 to Ras

5 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

H-, K- and N-Ras inhibit myeloid leukemia cell proliferation by a p21WAF1-dependent mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML).

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

The role of Rho GTPases in disease development

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

The molecular pathophysiology of myeloid leukaemias: Ras revisited.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

Proteins regulating Ras and its relatives

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

Role of FLT3 in leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

Growth factors and cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

Genomic structure of the downstream part of the human FLT3 gene: exon/intron structure conservation among genes encoding receptor tyrosine kinases (RTK) of subclass III

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

Protein prenylation, et cetera: signal transduction in two dimensions

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

Farnesyltransferase inhibitors: a new class of cancer chemotherapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

Flt3 signaling involves tyrosyl-phosphorylation of SHP-2 and SHIP and their association with Grb2 and Shc in Baf3/Flt3 cells

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

Phosphorylation of Shc by Src family kinases is necessary for stem cell factor receptor/c-kit mediated activation of the Ras/MAP kinase pathway and c-fos induction

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

Role of Ras/ERK-dependent pathway in the erythroid differentiation of K562 cells

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

Signal transduction from multiple Ras effectors

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

Oncogenic Ras activation of Raf/mitogen-activated protein kinase-independent pathways is sufficient to cause tumorigenic transformation

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

Colocalization of Ras and Ral on the membrane is required for Ras-dependent Ral activation through Ral GDP dissociation stimulator

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

p120 GAP modulates Ras activation of Jun kinases and transformation

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

Complexes of Ras.GTP with Raf-1 and mitogen-activated protein kinase kinase

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

A divergence in the MAP kinase regulatory network defined by MEK kinase and Raf

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

Regulation and interaction of pp90(rsk) isoforms with mitogen-activated protein kinases

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

MEK, ERK, and p90RSK are present on mitotic tubulin in Swiss 3T3 cells: a role for the MAP kinase pathway in regulating mitotic exit

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

An essential role for Rho, Rac, and Cdc42 GTPases in cell cycle progression through G1

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

Cytokine signaling through nonreceptor protein tyrosine kinases

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

JAKs, STATs and Src kinases in hematopoiesis

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

FMS mutations in myelodysplastic, leukemic, and normal subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year follow-up.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

c-kit proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

Systemic mastocytosis associated with acute myeloid leukaemia: report of two cases and detection of the c-kit mutation Asp-816 to Val

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho)

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

Internal tandem duplication of the FLT3 gene and clinical evaluation in childhood acute myeloid leukemia. The Children's Cancer and Leukemia Study Group, Japan

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

Biology of flt3 ligand and receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

Analysis of RAS gene mutations in acute myeloid leukemia by polymerase chain reaction and oligonucleotide probes

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

RAS gene mutations in childhood acute myeloid leukemia: a Pediatric Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

RAS mutations and clonality analysis in children with juvenile myelomonocytic leukemia (JMML)

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

Constitutive activation of mitogen-activated protein kinase pathway in acute leukemia cells

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

Lack of constitutive activation of MAP kinase pathway in human acute myeloid leukemia cells with N-Ras mutation

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

Regulation of constitutive STAT5 phosphorylation in acute myeloid leukemia blasts.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

Signal transducer and activator of transcription 3 activation is required for Asp(816) mutant c-Kit-mediated cytokine-independent survival and proliferation in human leukemia cells

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

Constitutive activation of FLT3 in acute myeloid leukaemia and its consequences for growth of 32D cells

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

In VivoDifferentiation of Mast Cells from Acute Myeloid Leukemia Blasts Carrying a Novel Activating Ligand-Independent C-kit Mutation

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

In vivo treatment of mutant FLT3-transformed murine leukemia with a tyrosine kinase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

Inhibition of FLT3-mediated transformation by use of a tyrosine kinase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

A farnesyl-protein transferase inhibitor induces p21 expression and G1 block in p53 wild type tumor cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

Non-Ras targets of farnesyltransferase inhibitors: focus on Rho.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

RhoB alteration is necessary for apoptotic and antineoplastic responses to farnesyltransferase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

Interferon-gamma-mediated activation of STAT1alpha regulates growth factor-induced mitogenesis.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900057-7

7 January 2021

10.1016/S0268-960X(02)00057-7

Identifiers

DOI

1 reference

5 August 2017

1 reference

PubMed ID

12490207